Bone disorders in type 1 multiple endocrine neoplasia syndrome: A review of clinical data
https://doi.org/10.47360/1995-4484-2021-97-102
Abstract
Primary hyperparathyroidism (PHPT) is a result of the parathyroid tumors, usually manifesting by elevated serum parathyroid hormone and hypercalcemia. One of the most common complications of PHPT are bone disorders. It mainly occurs as sporadic disease, while the remaining 5–10% is the component of hereditary syndromes, more often – type 1 multiple endocrine neoplasia syndrome (MEN1). MEN1 is caused by the germinal mutation of the oncosuppressor menin gene, founded in all cells of the human body, including the osteogenic cells. Data on the bone state in MEN1 is limited and contradictory. At the same time, some studies indicate that MEN1-related PHPT differs from sporadic form in bone manifestation, which can be presumably associated with the inadequate functioning of mutant menin. The results of experimental works suggest that menin plays an important role in the metabolism and differentiation of bone cells. This article is a literature review on this problem and contains information on the current clinical data on the bone state in patients with MEN1.
About the Authors
A. M. Gorbacheva
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests: нет
Russian Federation
Gorbacheva Anna
117036, Moscow, Dm. Ulyanova str., 11
Competing Interests: нет
A. K. Eremkina
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests: нет
Russian Federation
Anna K. Eremkina
117036, Moscow, Dm. Ulyanova str., 11
Competing Interests: нет
N. G. Mokrysheva
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests: нет
Russian Federation
Natalya G. Mokrysheva
117036, Moscow, Dm. Ulyanova str., 11
Competing Interests: нет
References
1. Dedov II, Melnichenko GA, Mokrysheva NG, Rozhinskaya LYa, Kuznetsov NS, Pigarova EA, et al. Primary hyperparathyroidism: The clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problemy endokrinologii = Problems of Endocrinology. 2016;62(6):40−77 (In Russ.). doi: 10.14341/probl201662640-77
2. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990−3011. doi: 10.1210/jc.2012-1230
3. Balsalobre Salmeron M, Rodriguez Gonzalez JM, Rios A, Febrero B, Paricio PP. Primary hyperparathyroidism associated with MEN1: Experience in 71 cases. Cir Esp. 2018;96(10):627−633. doi: 10.1016/j.ciresp.2018.06.014
4. Kaji H. Menin and bone metabolism. J Bone Miner Metab. 2012;30(4):381−387. doi: 10.1007/s00774-012-0355-3
5. Hendy GN, Kaji H, Canaff L. Cellular functions of menin. Adv Exp Med Biol. 2009;668:37−50. doi: 10.1007/978-1-4419-1664-8_4
6. Liu P, Lee S, Knoll J, Rauch A, Ostermay S, Luther J, et al. Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis. Cell Death Differ. 2017;24(4):672−682. doi: 10.1038/cdd.2016.165
7. Mokrysheva NG, Mirnaya SS, Dobreva EA, Maganeva IS, Kovaleva EV, Krupinova YuA, et al. Primary hyperparathyroidism in Russia according to the Registry. Problems of Endocrinology. 2019;65(5):300−310 (In Russ.). doi: 10.14341/probl10126
8. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598−602. doi: 10.1136/bmj.321.7261.598
9. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115−125. doi: 10.1038/nrendo.2017.104
10. De Geronimo S, Romagnoli E, Diacinti D, D’Erasmo E, Minisola S. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol. 2006;155(3):415−420. doi: 10.1530/eje.1.02225
11. Ejlsmark-Svensson H, Bislev LS, Lajlev S, Harsløf T, Rolighed L, Sikjaer T, et al. Prevalence and risk of vertebral fractures in primary hyperparathyroidism: A nested case-control study. J Bone Miner Res. 2018;33(9):1657−1664. doi: 10.1002/jbmr.3461
12. Rejnmark L, Ejlsmark-Svensson H. Effects of PTH and PTH hypersecretion on bone: A clinical perspective. Curr Osteoporos Rep. 2020;18(3):103−114. doi: 10.1007/s11914-020-00574-7
13. Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029−1040. doi: 10.1002/jbmr.1841
14. Hansen S, Beck Jensen J-E, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyper-parathyroidism: A case-control study using HR-pQCT. J Bone Miner Res. 2010;25(9):1941−1947.
15. Hansen S, Hauge EM, Rasmussen L, Beck Jensen J-E, Brixen K. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: A one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res. 2012;27(5):1150−1158. doi: 10.1002/jbmr.1540
16. Liu M, Williams J, Kuo J, Lee JA, Silverberg SJ, Walker MD. Risk factors for vertebral fracture in primary hyperparathyroidism. Endocrine. 2019;66(3):682−690. doi: 10.1007/s12020-019-02099-1
17. Grigorie D, Coles D, Sucaliuc A. Trabecular bone score (TBS) has a poor discriminative power for vertebral fractures in 153 Romani an patients with primary hyperparathyroidism. Acta Endocrinol (Bucharest, Rom 2005). 2018;14(2):208−212. doi: 10.4183/aeb.2018.208
18. Leere JS, Kruse C, Robaczyk M, Karmisholt J, Vestergaard P. Associations between trabecular bone score and biochemistry in surgically vs conservatively treated outpatients with primary hyperparathyroidism: A retrospective cohort study. Bone Rep. 2018;9:101−109. doi: 10.1016/j.bonr.2018.08.001
19. Rolighed L, Vestergaard P, Heickendorff L, Sikjaer T, Rejnmark L, Mosekilde L, et al. BMD improvements after operation for primary hyperparathyroidism. Langenbeck’s Arch Surg. 2013;398(1):113−120. doi: 10.1007/s00423-012-1026-5
20. Sharma J, Itum DS, Moss L, Chun-Li C, Weber C. Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism. World J Surg. 2014;38(6):1268−1273. doi: 10.1007/s00268-014-2555-6
21. Nomura R, Sugimoto T, Tsukamoto T, Yamauchi M, Sowa H, Chen Q, et al. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyper-parathyroidism: A six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf). 2004;60(3):335−342. doi: 10.1111/j.1365-2265.2004.01984.x
22. Lee D, Walker MD, Chen HY, Chabot JA, Lee JA, Kuo JH, et al. Bone mineral density changes after parathyroidectomy are dependent on biochemical profile. Surgery. 2019;165(1):107−113. doi: 10.1016/j.surg.2018.04.065
23. Lumachi F, Camozzi V, Ermani M, Lotto FDE, Luisetto G. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: A prospective study. Ann N Y Acad Sci. 2007;1117:357−361. doi: 10.1196/annals.1402.012
24. Koumakis E, Souberbielle J-C, Payet J, Sarfati E, Borderie D, Kahan A, et al. Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int. 2014;25(7):1963−1968. doi: 10.1007/s00198-014-2689-2
25. Mokrysheva NG. Parathyroid glands. Primary hyperparathyroidism . Moscow: Ltd “Meditsinskoe informatsionnoe agenstvo”; 2019;448 (In Russ.).
26. Zhang L, Liu X, Li H. Long-term skeletal outcomes of primary hyperparathyroidism patients after treatment with parathyroidec-tomy: A systematic review and meta-analysis. Horm Metab Res. 2018;50(3):242−249. doi: 10.1055/s-0043-125334
27. Lamas C, Navarro E, Casterás A, Portillo P, Alcázar V, Calatayud M, et al. MEN1-associated primary hyperparathyroidism in the Spanish registry: Clinical characteristics and surgical outcomes. Endocr Connect. 2019;8(10):1416−1424. doi: 10.1530/EC-19-0321
28. Lourenco DMJ, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JEM, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008;159(3):259−274. doi: 10.1530/EJE-08-0153
29. Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, et al. Multiple endocrine neoplasia type 1 in Japan: Establishment and analysis of a multicentre database. Clin Endocrinol (Oxf). 2012;76(4):533−539. doi: 10.1111/j.1365-2265.2011.04227.x
30. Kann PH, Bartsch D, Langer P, Hadji P, Pfützner A, Klüsener J. Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1. J Endocrinol Invest. 2012;35(6):573−579. doi: 10.3275/7880
31. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: Long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247(3):501−510. doi: 10.1097/SLA.0b013e31815efda5
32. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448−457. doi: 10.1007/s11894-010-0141-0
33. Tsoriev TT, Belaya ZE. Bone and joint structural impairments in acromegaly. Problemy endokrinologii = Problems of Endocrinology. 2018;64(2):121−129 (In Russ.). doi: 10.14341/probl9305
34. Panevin TS, Alekseeva LI, Melnichenko GA. Rheumatic manifestations of acromegaly. Osteoporosis and bone diseases. 2019;22(2):14−22 (In Russ.). doi: 10.14341/osteo11353
35. Lourenço DMJ, Coutinho FL, Toledo RA, Montenegro FLM, Correia-Deur JEM, Toledo SPA. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25(11):2382−2391. doi: 10.1002/jbmr.125
36. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, et al. Sporadic and MEN1-related primary hyperparathyroidism: Differences in clinical expression and severity. J Bone Miner Res. 2009;24(8):1404−1410. doi: 10.1359/jbmr.090304
37. Kong J, Wang O, Nie M, Shi J, Hu Y, Jiang Y, et al. Clinical and genetic analysis of multiple endocrine neoplasia type 1-related primary hyperparathyroidism in Chinese. PLoS One. 2016;11(11):e0166634. doi: 10.1371/journal.pone.0166634
38. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: Severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999;134(10):1119−1123. doi: 10.1001/archsurg.134.10.1119
39. Abdelhadi M, Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998;83(11):3845−3851. doi: 10.1210/jcem.83.11.5249
40. Coutinho FL, Lourenço DMJ, Toledo RA, Montenegro FLM, Correia-Deur JEM, Toledo SPA. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf). 2010;72(4):462−468. doi: 10.1111/j.1365-2265.2009.03672.x
41. Silva AM, Vodopivec D, Christakis I, Lyons G, Wei Q, Waguespack SG, et al. Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. Surgery. 2017;161(1):107−115. doi: 10.1016/j.surg.2016.06.065
42. Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Liu ILA, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122−1129. doi: 10.1210/jc.2012-4022
43. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: An update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171–177. doi: 10.1359/JBMR.050910
44. Giusti F, Tonelli F, Brandi ML. Primary hyperparathyroidism in multiple endocrine neoplasia type 1: When to perform surgery? Clinics (Sao Paulo). 2012;67Suppl 1:141−144. doi: 10.6061/clinics/2012(sup01)23
45. Tonelli F, Marini F, Giusti F, Brandi ML. Total and subtotal parathyroidectomy in young patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: Potential post-surgical benefits and complications. Front Endocrinol (Lausanne). 2018;9:558. doi: 10.3389/fendo.2018.00558
Review
For citations:
Gorbacheva A.M., Eremkina A.K., Mokrysheva N.G. Bone disorders in type 1 multiple endocrine neoplasia syndrome: A review of clinical data. Rheumatology Science and Practice. 2021;59(1):97-102. (In Russ.) https://doi.org/10.47360/1995-4484-2021-97-102
Views:
629
Email this article 